Immunotherapy - Before, During, and After
Archives for September 2021
Discussion List
-
New BCO Content on Recently Approved Immunotherapy Jemperli
Jemperli (chemical name: dostarlimab-gxly) is approved by the U.S. Food and Drug Administration (FDA) to treat mismatch repair deficient (dMMR) advanced-stage breast cancer that has grown during or after treatment if no other treatment options are available. Jemperli also is approved to treat dMMR advanced-stage…
Join Us on Zoom: Upcoming virtual meetups. Read more...